Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting a significant ownership position in Cytokinetics, Inc. common stock as of 12/31/2025.
The firm reports beneficial ownership of 17,716,372 shares, representing 14.5% of the outstanding common stock. It has sole voting power over 17,330,683 shares and sole dispositive power over 17,700,030 shares, with no shared voting or dispositive power.
T. Rowe Price states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cytokinetics, and it expressly denies being the beneficial owner of the securities beyond what is required for reporting.
Cytokinetics reported that the European Commission has approved MYQORZO® (aficamten) tablets at 5 mg, 10 mg, 15 mg and 20 mg strengths. The drug is indicated for adult patients with symptomatic, obstructive hypertrophic cardiomyopathy classified as New York Heart Association class II–III. This approval allows Cytokinetics to offer a novel allosteric, reversible inhibitor of cardiac myosin motor activity as a treatment option for this specific heart condition across the European Union.
Cytokinetics executive Andrew Callos reported an option exercise and share sale. On 02/05/2026, the EVP and Chief Commercial Officer exercised 15,000 non-qualified stock options at $23.26 per share and received 15,000 shares of common stock.
That same day, he sold 15,000 shares of common stock at $61.93 per share, leaving him with 50,440 shares of common stock held directly and 84,000 stock options remaining. The reported options were originally granted on 03/31/2022 and are scheduled to vest over four years, with an expiration date of 03/31/2031.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and matching share sale in company common stock. On February 2, 2026, he exercised 886 shares under an incentive stock option at
The same day, he sold 886 common shares at
Cytokinetics director James M. Daly reported receiving company stock as board compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to members of the board of directors. Following this transaction, Daly beneficially owned 197 shares of Cytokinetics common stock in direct ownership.
Cytokinetics director Nancy Wysenski reported receiving additional company stock as part of her board compensation. On 01/15/2026, she acquired 98 shares of common stock at a reported price of $63.44 per share, taken in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, she beneficially owned 30,971 shares of Cytokinetics common stock, held directly.
Cytokinetics director Wendell Wierenga reported a routine equity compensation transaction. On January 15, 2026, he acquired 98 shares of Cytokinetics common stock at $63.44 per share. According to the footnote, these fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this grant, he beneficially owns 32,542 common shares directly.
Cytokinetics director Edward M. Kaye, M.D. reported receiving additional company stock as part of his board compensation. On 01/15/2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. According to the filing, these were fully vested shares issued in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, Dr. Kaye directly owned 10,174 shares of Cytokinetics common stock.
Cytokinetics director John T. Henderson reported receiving 334 shares of Cytokinetics common stock on 01/15/2026 at a value of $63.44 per share. These fully vested shares were issued in lieu of a cash retainer under the company’s Equity in Lieu of Cash Retainer Option available to members of the Board of Directors.
After this award, Henderson beneficially owned 74,912 shares of Cytokinetics common stock directly, and an additional 83 shares indirectly through his spouse. This filing reflects routine equity compensation for board service rather than an open-market share purchase.
Cytokinetics director Robert Arthur Harrington reported receiving additional company stock as compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These were fully vested shares received in lieu of a cash retainer under an equity compensation option available to members of the Board of Directors.
Following this transaction, Harrington beneficially owned 18,739 shares of Cytokinetics common stock in direct ownership. The filing reflects routine director compensation paid in stock rather than cash, with no sales reported.